Thursday , July 18 2019
Breaking News
Home / BUSINESS / EQUITIES / Torrent, Glenmark sign licensing agreement for co-marketing of Remogliflozin Etaboriate in India

Torrent, Glenmark sign licensing agreement for co-marketing of Remogliflozin Etaboriate in India

Torrent Pharmaceuticals (Torrent) and Glenmark Pharmaceuticals (Glenmark) have entered into a non-exclusive sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India. Under the terms of the agreement, Glenmark will receive license fees and royalties for the non-exclusive sub-license rights from Torrent. Glenmark will manufacture and supply Remogliflozin, while Torrent will market the drug under its own trademark ‘Zucator’ in India.

Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.

Click & Download Udaipur Kiran App to read Latest News

Leave a Reply

Your email address will not be published. Required fields are marked *

*

Inline

Click & Download Udaipur Kiran App to read Latest News

Inline

Click & Download Udaipur Kiran App to read Latest News